L Herszenyi
Overview
Explore the profile of L Herszenyi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pentek M, Gulacsi L, Herszenyi L, Banai J, Palatka K, Lakatos P, et al.
Colorectal Dis
. 2020 Sep;
23(1):105-113.
PMID: 32920967
Aim: The aim was to explore the subjective health expectations (sHE) of patients with Crohn's disease (CD) for both the near future and the elderly. Method: A cross-sectional survey was...
2.
Mihaly E, Szekely H, Herszenyi L, Wikonkal N, Tulassay Z
Aliment Pharmacol Ther
. 2013 Dec;
39(2):232-3.
PMID: 24330244
No abstract available.
3.
Molnar T, Farkas K, Miheller P, Nyari T, Szepes Z, Herszenyi L, et al.
J Crohns Colitis
. 2010 Dec;
2(4):322-6.
PMID: 21172231
Unlabelled: The high cost of infliximab inhibits the regular retreatment of all patients in Hungary with Crohn's disease (CD) after beneficial induction therapy. This study is set out to evaluate...
4.
Hritz I, Herszenyi L, Molnar B, Tulassay Z, Pronai L
Int J Immunopathol Pharmacol
. 2005 Feb;
18(1):75-84.
PMID: 15698513
Proton pump inhibitor (PPI) co-therapy is considered the best strategy in preventing gastrointestinal complications during non-steroidal anti-inflammatory drug (NSAID) treatment, but there is limited information available on its effect on...
5.
Pronai L, Hritz I, Molnar B, Herszenyi L, Tulassay Z
Int J Immunopathol Pharmacol
. 2003 Oct;
16(2 Suppl):23-30.
PMID: 14552701
COX-2 selective inhibitors (coxibs) have been developed with the primary aim to reduce/avoid gastrointestinal (GI) toxicity observed during conventional (non-selective) non-steroidal anti-inflammatory (NSAID) therapy. Coxibs have clearly and convincingly been...
6.
Herszenyi L, Tulassay Z
Orv Hetil
. 2001 Oct;
142(36):1953-61.
PMID: 11680100
Proton pump inhibitors (PPI) have influenced dramatically the management of acid-related disorders in recent years. They all have a broadly similar mechanism of action. There are some differences however, between...
7.
Juhasz M, Pronai L, Zagoni T, Nemeth A, Herszenyi L, Schandl L, et al.
Orv Hetil
. 2000 May;
141(17):911-4.
PMID: 10827472
There are several possible methods to detect H. pylori in the gastric mucosa. The aim of our prospective study was to evaluate the diagnostic value of these tests and to...
8.
Herszenyi L, Plebani M, Carraro P, De Paoli M, Roveroni G, Cardin R, et al.
Clin Chim Acta
. 2000 Feb;
291(2):171-87.
PMID: 10675722
Cysteine and serine proteases are involved in cancer invasion and metastasis. In the past few years we investigated the tissue levels of these proteases in gastric cancer (GC), gastric precancerous...
9.
Herszenyi L, Plebani M, Carraro P, De Paoli M, Roveroni G, Cardin R, et al.
Cancer
. 1999 Oct;
86(7):1135-42.
PMID: 10506696
Background: Cathepsin B (CATB) and cathepsin L (CATL), which are cysteine proteases, urokinase-(UPA) and tissue-type plasminogen activator (TPA), both serine proteases, and their inhibitor type-1 (PAI-1) are believed to play...
10.
Herszenyi L, Farinati F, Plebani M, Istvan G, Sapi Z, Carraro P, et al.
Orv Hetil
. 1999 Sep;
140(33):1833-6.
PMID: 10489782
Cysteine proteases [Cathepsin B and L (CATB, CATL)] and the serine protease urokinase type plasminogen activator (UPA) with its inhibitor type-1 (PAI-1) are thought to play an important part in...